Houston, TX · Founded 2015 · Privately Held (backing)
Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of patients who have responded exceptionally well to checkpoint inhibition. OncoResponse is based in Houston, TX and was founded in 2015. Its last reported valuation was $36 million in May 2023. It has raised $180 million across 2 recorded rounds; the latest was a $6 million early-stage round in Apr 2025.
Last reported valuation
$36.0M
Oct 2026
Priced at
—
Total raised
$180.0M
Last round
Early Stage VC
Apr 2025
No prints on record
No secondary trades in OncoResponse shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of OncoResponse with a free account
·The complete investor list: 25 names
·Watch OncoResponse: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of OncoResponse stock.
